Pureos Bioventures Expands Fund Size to USD 205 Million

The supporters of the first Pureos fund include strategic partners, such as pharmaceutical and biotech companies as well as a large contract manufacturer, family offices, pension funds, fund-of-funds and other institutional investors. With its committed capital, Pureos is the largest institutional Swiss VC fund that solely invests in private biotech companies.

Pureos will exclusively invest in innovative private drug development companies with an emphasis on novel biological drugs and emerging modalities such as nucleic acid, cell- and gene therapies. The fund’s portfolio companies are built on scientific excellence with strong teams to develop therapies across a broad spectrum of indications including oncology, immunology, ophthalmology, rare diseases and neuroscience. The fund invests globally, with a primary focus on Switzerland and Europe. The Pureos team consists of experienced venture capitalists, biotech entrepreneurs and drug developers.

For its first fund, Pureos is building a balanced portfolio of 17-20 pre-clinical and clinical-stage companies. Its initial investments include Swiss companies such as Alentis Therapeutics, Araris and NovaGo Therapeutics. In March, Lava Therapeutics went public on NASDAQ, representing a first IPO exit in the Pureos portfolio.